Wendy Rowan started her career at Guy’s Hospital Medical School, before transitioning to industry. She has worked for GSK and its legacy companies for over thirty years. Immunology has been a common theme throughout my career, working on aspects of both innate and adaptive immunity in respiratory and autoimmune diseases. In April 2019, she joined the Novel Human Genetics Research Unit with a focus on using genetics to guide target selection for drug discovery. With the aim of reducing attrition in drug discovery, she has a long-standing interest in developing and accessing better human translational models for target validation, lead discovery and candidate selection, including safety assessment and PK/PD profiling.